Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 8—August 2013
Research

Comparison of 2 Assays for Diagnosing Rotavirus and Evaluating Vaccine Effectiveness in Children with Gastroenteritis

Jacqueline E. TateComments to Author , Slavica Mijatovic-Rustempasic, Ka Ian Tam, Freda C. Lyde, Daniel C. Payne, Peter Szilagyi, Kathryn Edwards, Mary Allen Staat, Geoffrey A. Weinberg, Caroline B. Hall, James Chappell, Monica McNeal, Jon R. Gentsch, Michael D. Bowen, and Umesh D. Parashar
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.E. Tate, S. Mijatovic-Rustempasic, K.I. Tam, F.C. Lyde, D.C. Payne, J.R. Gentsch, M.D. Bowen, U.D. Parashar); University of Rochester School of Medicine and Dentistry, Rochester, New York, USA (P. Szilagyi, G.A. Weinberg, C.B. Hall); Vanderbilt University Medical Center, Nashville, Tennessee, USA (K. Edwards, J. Chappell); Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA (M.A. Staat, M. McNeal)

Main Article

Table 3

VE using different case and control definitions in a study of the use of diagnostic assays for rotavirus in children >8 months of age with acute gastroenteritis, 3 New Vaccine Surveillance Network sites (USA), October 2008–October 2009*

Definition, no. doses
 No. (%) cases
 No. (%) controls
 % VE (95% CI)†
EIA+ cases and EIA− controls 128 302
0 98 (77) 115 (38) NA
1 6 (5) 15 (5) 51 (−38 to 83)
2 4 (3) 43 (14) 90 (70–97)
3
 20 (16)
 129 (43)
 84 (71–91)
EIA+ case and qRT-PCR− controls 128 266
0 98 (77) 99 (37) NA
1 6 (5) 13 (5) 47 (−53 to 82)
2 4 (3) 40 (15) 89 (66–96)
3
 20 (16)
 114 (43)
 83 (68–91)
qRT-PCR+ cases and qRT-PCR− controls 164 266
0 114 (70) 99 (37) NA
1 8 (5) 13 (5) 47 (−38 to 80)
2 7 (4) 40 (15) 85 (64–94)
3
 35 (21)
 114 (43)
 75 (58–86)
EIA- and qRT-PCR+ cases vs. EIA- and qRT-PCR- controls 36 266
0 16 (44) 99 (37) NA
1 2 (6) 13 (5) 21 (−309 to 80)
2 3 (8) 40 (15) 47 (−108 to 87)
3 15 (42) 114 (43) 14 (−105 to 64)

*VE, vaccine effectiveness; EIA, enzyme immunoassay; +, positive; −, negative; NA, not applicable; qRT-PCR, semiquantitative reverse transcription PCR.
†Controlling for age (in months), month and year of birth, and month of illness onset in the analysis.

Main Article

Page created: July 02, 2013
Page updated: July 02, 2013
Page reviewed: July 02, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external